Archemix - Hemophilia Assets' Unit Acquisition

Archemix - Hemophilia Assets raised a round of funding on November 20, 2010. Investors include Baxter International.

Archemix discovers, develops, and commercializes therapeutic aptamers for the prevention and treatment of chronic and acute diseases. The Company's aptamer product candidates include ARC1779 for throm…

Articles about Archemix - Hemophilia Assets' Unit Acquisition: